Research progress of pH-responsive drug delivery systems in cancer immunotherapy

WANG Shihao; LIU Lifeng; DING Yang; LI Suxin

doi:10.11665/j.issn.1000-5048.2024011902

Journal of China Pharmaceutical University > 2024 > 55(4): 522-529. > DOI: 10.11665/j.issn.1000-5048.2024011902

WANG Shihao, LIU Lifeng, DING Yang, et al. Research progress of pH-responsive drug delivery systems in cancer immunotherapy[J]. J China Pharm Univ, 2024, 55(4): 522 − 529. DOI: 10.11665/j.issn.1000-5048.2024011902

Citation:

PDF (531 KB)

Research progress of pH-responsive drug delivery systems in cancer immunotherapy

Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China

More Information

Received Date: January 18, 2024

Graphical Abstract

Abstract

Abstract

Cancer immunotherapy, which is an attractive strategy harnessing the host's own immune system to remove tumor cells, has been widely used in clinical practice, yet with low response rate and immune-related adverse events. Unlike traditional chemotherapy, the targets of immunotherapy exhibit high spatial heterogeneity and are distributed in different cell types or secondary organelles, resulting in off-target and on-target toxicity, which greatly reduces the efficacy and safety of treatment. Due to the altered metabolic level, tumor tissues often display a lower pH than normal tissues. In addition, the endocytosis pathway is accompanied by continuous pumping of protons. Therefore, the variation of environmental pH values could serve as an ideal stimulus for precise drug delivery and release. In recent years, pH-responsive materials (e.g., polymers, biomacromolecules, lipid nanoparticles, biofilm, inorganic nanoparticles, and metal-organic frameworks) have been widely investigated in the field of cancer immunotherapy. This paper summarizes recent strategies of pH-responsive drug delivery systems based on different types of carriers, aiming to provide some reference for the design of next generation of tumor-targeting formulations in cancer immunotherapy.
- tumor,
- immunotherapy,
- drug delivery system,
- pH-responsive,
- targeted delivery

FullText(HTML)

References (43)

References

[1]	Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion[J]. Nat Rev Cancer, 2021, 21(5): 298-312. doi: 10.1038/s41568-021-00339-z
[2]	Sharma P, Goswami S, Raychaudhuri D, et al. Immune checkpoint therapy-current perspectives and future directions[J]. Cell, 2023, 186(8): 1652-1669. doi: 10.1016/j.cell.2023.03.006
[3]	Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors[J]. Nat Rev Dis Primers, 2020, 6(1): 38. doi: 10.1038/s41572-020-0160-6
[4]	Xiao Y, Zhang T, Ma XB, et al. Microenvironment-responsive prodrug-induced pyroptosis boosts cancer immunotherapy[J]. Adv Sci, 2021, 8(24): e2101840. doi: 10.1002/advs.202101840
[5]	Wang YL, Khan A, Liu YX, et al. Chitosan oligosaccharide-based dual pH responsive nano-micelles for targeted delivery of hydrophobic drugs[J]. Carbohydr Polym, 2019, 223: 115061. doi: 10.1016/j.carbpol.2019.115061
[6]	Jiang DD, Gao T, Liang S, et al. Lymph node delivery strategy enables the activation of cytotoxic T lymphocytes and natural killer cells to augment cancer immunotherapy[J]. ACS Appl Mater Interfaces, 2021, 13(19): 22213-22224. doi: 10.1021/acsami.1c03709
[7]	Cappellesso F, Orban MP, Shirgaonkar N, et al. Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer[J]. Nat Cancer, 2022, 3(12): 1464-1483. doi: 10.1038/s43018-022-00470-2
[8]	Luo L, Xu FS, Peng HL, et al. Stimuli-responsive polymeric prodrug-based nanomedicine delivering nifuroxazide and doxorubicin against primary breast cancer and pulmonary metastasis[J]. J Control Release, 2020, 318: 124-135. doi: 10.1016/j.jconrel.2019.12.017
[9]	Xia CY, Yin S, Xu SS, et al. Low molecular weight heparin-coated and dendrimer-based core-shell nanoplatform with enhanced immune activation and multiple anti-metastatic effects for melanoma treatment[J]. Theranostics, 2019, 9(2): 337-354. doi: 10.7150/thno.29026
[10]	Su T, Cheng FR, Qi JL, et al. Responsive multivesicular polymeric nanovaccines that codeliver STING agonists and neoantigens for combination tumor immunotherapy[J]. Adv Sci, 2022, 9(23): e2201895. doi: 10.1002/advs.202201895
[11]	Guo K, Liu YX, Ding M, et al. Enhanced drug release from a pH-responsive nanocarrier can augment colon cancer treatment by blocking PD-L1 checkpoint and consuming tumor glucose[J]. Mater Des, 2022, 219: 110824. doi: 10.1016/j.matdes.2022.110824
[12]	Li C, Wang X, Song H, et al. Current multifunctional albumin-based nanoplatforms for cancer multi-mode therapy[J]. Asian J Pharm Sci, 2020, 15(1): 1-12. doi: 10.1016/j.ajps.2018.12.006
[13]	Fan Q, Li ZH, Yin J, et al. Inhalable pH-responsive DNA tetrahedron nanoplatform for boosting anti-tumor immune responses against metastatic lung cancer[J]. Biomaterials, 2023, 301: 122283. doi: 10.1016/j.biomaterials.2023.122283
[14]	Li XY, Luo Y, Huang ZJ, et al. Multifunctional liposomes remodeling tumor immune microenvironment for tumor chemoimmunotherapy[J]. Small Methods, 2023, 7(5): e2201327. doi: 10.1002/smtd.202201327
[15]	Yuba, Kado Y, Kasho N, et al. Cationic lipid potentiated the adjuvanticity of polysaccharide derivative-modified liposome vaccines[J]. J Control Release, 2023, 362: 767-776. doi: 10.1016/j.jconrel.2022.10.016
[16]	Yang GX, Zhou D, Dai Y, et al. Construction of PEI-EGFR-PD-L1-siRNA dual functional nano-vaccine and therapeutic efficacy evaluation for lung cancer[J]. Thorac Cancer, 2022, 13(21): 2941-2950. doi: 10.1111/1759-7714.14618
[17]	Gong CN, Yu XY, Zhang W, et al. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles[J]. J Nanobiotechnology, 2021, 19(1): 58. doi: 10.1186/s12951-021-00805-8
[18]	Zhang XQ, Wei ZH, Yong TY, et al. Cell microparticles loaded with tumor antigen and resiquimod reprogram tumor-associated macrophages and promote stem-like CD8⁺ T cells to boost anti-PD-1 therapy[J]. Nat Commun, 2023, 14(1): 5653. doi: 10.1038/s41467-023-41438-9
[19]	Zheng YD, Zhang ZZ, Liu Q, et al. Multifunctional nanomodulators regulate multiple pathways to enhance antitumor immunity[J]. ACS Appl Bio Mater, 2020, 3(7): 4635-4642. doi: 10.1021/acsabm.0c00513
[20]	Yang GB, Xu LG, Chao Y, et al. Hollow MnO₂ as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses[J]. Nat Commun, 2017, 8(1): 902. doi: 10.1038/s41467-017-01050-0
[21]	Li YH, Gong SH, Pan W, et al. A tumor acidity activatable and Ca²⁺-assisted immuno-nanoagent enhances breast cancer therapy and suppresses cancer recurrence[J]. Chem Sci, 2020, 11(28): 7429-7437. doi: 10.1039/D0SC00293C
[22]	Zhang HJ, Chen W, Gong K, et al. Nanoscale zeolitic imidazolate framework-8 as efficient vehicles for enhanced delivery of CpG oligodeoxynucleotides[J]. ACS Appl Mater Interfaces, 2017, 9(37): 31519-31525. doi: 10.1021/acsami.7b09583
[23]	Dai Z, Wang QY, Tang J, et al. Immune-regulating bimetallic metal-organic framework nanoparticles designed for cancer immunotherapy[J]. Biomaterials, 2022, 280: 121261. doi: 10.1016/j.biomaterials.2021.121261
[24]	Xu R, Yang J, Qian Y, et al. Ferroptosis/pyroptosis dual-inductive combinational anti-cancer therapy achieved by transferrin decorated nanoMOF[J]. Nanoscale Horiz, 2021, 6(4): 348-356. doi: 10.1039/D0NH00674B
[25]	Xu MM, Chang YC, Zhu GH, et al. Transforming cold tumors into hot ones with a metal-organic framework-based biomimetic nanosystem for enhanced immunotherapy[J]. ACS Appl Mater Interfaces, 2023, 15(14): 17470-17484. doi: 10.1021/acsami.2c21005
[26]	Lin F, Chen L, Zhang H, et al. Bioorthogonal prodrug-antibody conjugates for on-target and on-demand chemotherapy[J]. CCS Chem, 2019, 1(2): 226-236. doi: 10.31635/ccschem.019.20180038
[27]	Jin C, Wang Y, Li YF, et al. Doxorubicin-near infrared dye conjugate induces immunogenic cell death to enhance cancer immunotherapy[J]. Int J Pharm, 2021, 607: 121027. doi: 10.1016/j.ijpharm.2021.121027
[28]	Zeng T, Zang WJ, Xiao H, et al. Carrier-free nanovaccine: an innovative strategy for ultrahigh melanoma neoantigen loading[J]. ACS Nano, 2023, 17(18): 18114-18127. doi: 10.1021/acsnano.3c04887
[29]	Mao LZ, Ma PQ, Luo X, et al. Stimuli-responsive polymeric nanovaccines toward next-generation immunotherapy[J]. ACS Nano, 2023, 17(11): 9826-9849. doi: 10.1021/acsnano.3c02273
[30]	Banstola A, Poudel K, Kim JO, et al. Recent progress in stimuli-responsive nanosystems for inducing immunogenic cell death[J]. J Control Release, 2021, 337: 505-520. doi: 10.1016/j.jconrel.2021.07.038
[31]	Tang MM, Chen BL, Xia HM, et al. pH-gated nanoparticles selectively regulate lysosomal function of tumour-associated macrophages for cancer immunotherapy[J]. Nat Commun, 2023, 14(1): 5888. doi: 10.1038/s41467-023-41592-0
[32]	Carson CS, Becker KW, Garland KM, et al. A nanovaccine for enhancing cellular immunity via cytosolic co-delivery of antigen and polyIC RNA[J]. J Control Release, 2022, 345: 354-370. doi: 10.1016/j.jconrel.2022.03.020
[33]	Cen D, Ge QW, Xie CK, et al. ZnS@BSA nanoclusters potentiate efficacy of cancer immunotherapy[J]. Adv Mater, 2021, 33(49): e2104037. doi: 10.1002/adma.202104037
[34]	Gumala A, Sutriyo S. Active targeting gold nanoparticle for chemotherapy drug delivery: a review[J]. Pharm Sci-Iran, 2022, 28(3): 342-354.
[35]	Kundu M, Chatterjee S, Ghosh N, et al. Tumor targeted delivery of umbelliferone via a smart mesoporous silica nanoparticles controlled-release drug delivery system for increased anticancer efficiency[J]. Mater Sci Eng C Mater Biol Appl, 2020, 116: 111239. doi: 10.1016/j.msec.2020.111239
[36]	Zhu WW, Dong ZL, Fu TT, et al. Modulation of hypoxia in solid tumor microenvironment with MnO₂ nanoparticles to enhance photodynamic therapy[J]. Adv Funct Materials, 2016, 26(30): 5490-5498. doi: 10.1002/adfm.201600676
[37]	Poostforooshan J, Belbekhouche S, Shaban M, et al. Aerosol-assisted synthesis of tailor-made hollow mesoporous silica microspheres for controlled release of antibacterial and anticancer agents[J]. ACS Appl Mater Interfaces, 2020, 12(6): 6885-6898. doi: 10.1021/acsami.9b20510
[38]	Özsoy M, Atiroğlu V, Guney Eskiler G, et al. A protein-sulfosalicylic acid/boswellic acids @metal-organic framework nanocomposite as anticancer drug delivery system[J]. Colloids Surf B Biointerfaces, 2021, 204: 111788. doi: 10.1016/j.colsurfb.2021.111788
[39]	Gao P, Chen YY, Pan W, et al. Antitumor agents based on metal-organic frameworks[J]. Angew Chem Int Ed Engl, 2021, 60(31): 16763-16776. doi: 10.1002/anie.202102574
[40]	Nong WQ, Wu J, Ghiladi RA, et al. The structural appeal of metal–organic frameworks in antimicrobial applications[J]. Coord Chem Rev, 2021, 442: 214007. doi: 10.1016/j.ccr.2021.214007
[41]	Hou DY, Cheng DB, Zhang NY, et al. In vivo assembly enhanced binding effect augments tumor specific ferroptosis therapy[J]. Nat Commun, 2024, 15(1): 454.
[42]	Zheng YC, Sun LQ, Guo JM, et al. The crosstalk between ferroptosis and anti-tumor immunity in the tumor microenvironment: molecular mechanisms and therapeutic controversy[J]. Cancer Commun, 2023, 43(10): 1071-1096. doi: 10.1002/cac2.12487
[43]	Bargh JD, Isidro-Llobet A, Parker JS, et al. Cleavable linkers in antibody-drug conjugates[J]. Chem Soc Rev, 2019, 48(16): 4361-4374. doi: 10.1039/C8CS00676H

Cited By

Get Citation

PDF

XML

Article views (708) PDF downloads (104)

Turn off MathJax

Article Contents

Abstract

References

Research progress of pH-responsive drug delivery systems in cancer immunotherapy

Abstract

References

Catalog

Export File

Citation

Format

Content